{{Rsnum
|rsid=2306541
|Gene=CHFR
|Chromosome=12
|position=132851656
|Orientation=plus
|ReferenceAllele=C
|MissenseAllele=T
|GMAF=0.2433
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=CHFR
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 13.3 | 39.8 | 46.9
| HCB | 3.6 | 31.4 | 65.0
| JPT | 0.9 | 30.6 | 68.5
| YRI | 5.4 | 28.6 | 66.0
| ASW | 5.3 | 43.9 | 50.9
| CHB | 3.6 | 31.4 | 65.0
| CHD | 2.8 | 40.4 | 56.9
| GIH | 13.9 | 34.7 | 51.5
| LWK | 6.4 | 38.5 | 55.0
| MEX | 6.9 | 32.8 | 60.3
| MKK | 9.7 | 39.4 | 51.0
| TSI | 2.0 | 44.6 | 53.5
| HapMapRevision=28
}}{{Venter SNP
|rsid=2306541
|allele=A
|frequency=0.304
|uid=1103649581692
|type=homozygous_SNP
|hugo=CHFR
|ensembl gene=ENSG00000072609
|ensembl transcript=ENST00000266880
|sift=TOLERATED
|disease=Defects in CHFR may be involved in colon, lung and esophageal cancers and non small cell lung carcinomas (NSCLC). In addition, CHFR gene is silenced in many primary cancers because of CpG methylation and deacetylated histones on its promoter region. This however raises the question of whether CHFR silencing is a consequence or a cause of primary cancers.
}}

{{GET Evidence
|gene=CHFR
|aa_change=Ala497Val
|aa_change_short=A497V
|impact=not reviewed
|qualified_impact=Insufficiently evaluated not reviewed
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2306541
|overall_frequency_n=3006
|overall_frequency_d=10758
|overall_frequency=0.27942
|n_genomes=3
|n_genomes_annotated=0
|n_haplomes=5
|n_articles=0
|n_articles_annotated=0
|pph2_score=0.688
|nblosum100=2
|autoscore=0
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}